Vera Therapeutics, Inc.
Key Metrics
- Previous Close
- $26.20
- 52-Week Range
- $25.34 – $56.05
- Market Cap
- $1.85B
- P/E (TTM)
- —
- EPS (TTM)
- -5.90
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.55
- PEG Ratio
- —
- Return on Equity
- -113.46%
- Return on Assets
- -54.35%
- Gross Margin
- 67.93%
- Operating Margin
- -4160.07%
- Profit Margin
- 0.00%
- Current Ratio
- 7.91
- Debt/Equity
- 0.23
- Total Debt
- $76.79M
- Free Cash Flow
- $-244.62M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.54B
Market Snapshot
About
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. The company is advancing atacicept, a novel fusion protein, for IgA nephropathy and other autoimmune conditions. Vera aims to address unmet medical needs in complement-mediated and autoimmune disorders.